Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population.

Wilson TR, Yu J, Lu X, Spoerke JM, Xiao Y, O'Brien C, Savage HM, Huw LY, Zou W, Koeppen H, Forrest WF, Fridlyand J, Fu L, Tam R, Schleifman EB, Sumiyoshi T, Molinero L, Hampton GM, O'Shaughnessy JA, Lackner MR.

NPJ Breast Cancer. 2016 Jul 13;2:16022. doi: 10.1038/npjbcancer.2016.22. eCollection 2016.

2.

Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder Cancers.

Kim D, Choi Y, Ireland J, Foreman O, Tam RN, Patel R, Schleifman EB, Motlhabi M, French D, Wong CV, Peters E, Molinero L, Raja R, Amler LC, Hampton GM, Lackner MR, Kabbarah O.

PLoS One. 2016 Nov 15;11(11):e0165856. doi: 10.1371/journal.pone.0165856. eCollection 2016.

3.

Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter.

Qu X, Sandmann T, Frierson H Jr, Fu L, Fuentes E, Walter K, Okrah K, Rumpel C, Moskaluk C, Lu S, Wang Y, Bourgon R, Penuel E, Pirzkall A, Amler L, Lackner MR, Tabernero J, Hampton GM, Kabbarah O.

Oncogene. 2016 Dec 15;35(50):6403-6415. doi: 10.1038/onc.2016.170. Epub 2016 Jun 6.

4.

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.

Spoerke JM, Gendreau S, Walter K, Qiu J, Wilson TR, Savage H, Aimi J, Derynck MK, Chen M, Chan IT, Amler LC, Hampton GM, Johnston S, Krop I, Schmid P, Lackner MR.

Nat Commun. 2016 May 13;7:11579. doi: 10.1038/ncomms11579.

5.

Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β.

Nakanishi Y, Walter K, Spoerke JM, O'Brien C, Huw LY, Hampton GM, Lackner MR.

Cancer Res. 2016 Mar 1;76(5):1193-203. doi: 10.1158/0008-5472.CAN-15-2201. Epub 2016 Jan 12.

6.

Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples.

Wilson TR, Xiao Y, Spoerke JM, Fridlyand J, Koeppen H, Fuentes E, Huw LY, Abbas I, Gower A, Schleifman EB, Desai R, Fu L, Sumiyoshi T, O'Shaughnessy JA, Hampton GM, Lackner MR.

Breast Cancer Res Treat. 2014 Nov;148(2):315-25. doi: 10.1007/s10549-014-3163-8. Epub 2014 Oct 22.

7.

Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing.

Zhang L, Chen L, Sah S, Latham GJ, Patel R, Song Q, Koeppen H, Tam R, Schleifman E, Mashhedi H, Chalasani S, Fu L, Sumiyoshi T, Raja R, Forrest W, Hampton GM, Lackner MR, Hegde P, Jia S.

Oncologist. 2014 Apr;19(4):336-43. doi: 10.1634/theoncologist.2013-0180. Epub 2014 Mar 24.

8.

Discovery and development of DNA methylation-based biomarkers for lung cancer.

Walter K, Holcomb T, Januario T, Yauch RL, Du P, Bourgon R, Seshagiri S, Amler LC, Hampton GM, S Shames D.

Epigenomics. 2014 Feb;6(1):59-72. doi: 10.2217/epi.13.81.

PMID:
24579947
9.

High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.

Bourgon R, Lu S, Yan Y, Lackner MR, Wang W, Weigman V, Wang D, Guan Y, Ryner L, Koeppen H, Patel R, Hampton GM, Amler LC, Wang Y.

Clin Cancer Res. 2014 Apr 15;20(8):2080-91. doi: 10.1158/1078-0432.CCR-13-3114. Epub 2014 Feb 26.

10.

Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers.

Schleifman EB, Desai R, Spoerke JM, Xiao Y, Wong C, Abbas I, O'Brien C, Patel R, Sumiyoshi T, Fu L, Tam RN, Koeppen H, Wilson TR, Raja R, Hampton GM, Lackner MR.

PLoS One. 2014 Feb 10;9(2):e88401. doi: 10.1371/journal.pone.0088401. eCollection 2014.

11.

Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer.

Huw LY, O'Brien C, Pandita A, Mohan S, Spoerke JM, Lu S, Wang Y, Hampton GM, Wilson TR, Lackner MR.

Oncogenesis. 2013 Dec 23;2:e83. doi: 10.1038/oncsis.2013.46.

12.

HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors.

Penuel E, Li C, Parab V, Burton L, Cowan KJ, Merchant M, Yauch RL, Patel P, Peterson A, Hampton GM, Lackner MR, Hegde PS.

Mol Cancer Ther. 2013 Jun;12(6):1122-30. doi: 10.1158/1535-7163.MCT-13-0015. Epub 2013 Mar 27.

13.

High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck.

Shames DS, Carbon J, Walter K, Jubb AM, Kozlowski C, Januario T, Do A, Fu L, Xiao Y, Raja R, Jiang B, Malekafzali A, Stern H, Settleman J, Wilson TR, Hampton GM, Yauch RL, Pirzkall A, Amler LC.

PLoS One. 2013;8(2):e56765. doi: 10.1371/journal.pone.0056765. Epub 2013 Feb 28. Erratum in: PLoS One. 2013;8(6). doi:10.1371/annotation/63f57c72-c869-4ef5-94d1-3cbd6c2e3678. AnDo [corrected to Do, An].

14.

Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.

Spoerke JM, O'Brien C, Huw L, Koeppen H, Fridlyand J, Brachmann RK, Haverty PM, Pandita A, Mohan S, Sampath D, Friedman LS, Ross L, Hampton GM, Amler LC, Shames DS, Lackner MR.

Clin Cancer Res. 2012 Dec 15;18(24):6771-83. doi: 10.1158/1078-0432.CCR-12-2347. Epub 2012 Nov 7.

15.

Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary.

Bauerschlag D, Bräutigam K, Moll R, Sehouli J, Mustea A, Salehin D, Krajewska M, Reed JC, Maass N, Hampton GM, Meinhold-Heerlein I.

J Cancer Res Clin Oncol. 2013 Feb;139(2):347-55. doi: 10.1007/s00432-012-1334-8. Epub 2012 Oct 23.

PMID:
23090696
16.

Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.

Punnoose EA, Atwal S, Liu W, Raja R, Fine BM, Hughes BG, Hicks RJ, Hampton GM, Amler LC, Pirzkall A, Lackner MR.

Clin Cancer Res. 2012 Apr 15;18(8):2391-401. doi: 10.1158/1078-0432.CCR-11-3148. Epub 2012 Apr 5.

17.

ERK inhibition overcomes acquired resistance to MEK inhibitors.

Hatzivassiliou G, Liu B, O'Brien C, Spoerke JM, Hoeflich KP, Haverty PM, Soriano R, Forrest WF, Heldens S, Chen H, Toy K, Ha C, Zhou W, Song K, Friedman LS, Amler LC, Hampton GM, Moffat J, Belvin M, Lackner MR.

Mol Cancer Ther. 2012 May;11(5):1143-54. doi: 10.1158/1535-7163.MCT-11-1010. Epub 2012 Mar 8.

18.

DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer.

Walter K, Holcomb T, Januario T, Du P, Evangelista M, Kartha N, Iniguez L, Soriano R, Huw L, Stern H, Modrusan Z, Seshagiri S, Hampton GM, Amler LC, Bourgon R, Yauch RL, Shames DS.

Clin Cancer Res. 2012 Apr 15;18(8):2360-73. doi: 10.1158/1078-0432.CCR-11-2635-T. Epub 2012 Jan 19.

19.

Cdc6 and cyclin E2 are PTEN-regulated genes associated with human prostate cancer metastasis.

Wu Z, Cho H, Hampton GM, Theodorescu D.

Neoplasia. 2009 Jan;11(1):66-76.

20.
21.

An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma.

Meinhold-Heerlein I, Bauerschlag D, Zhou Y, Sapinoso LM, Ching K, Frierson H Jr, Bräutigam K, Sehouli J, Stickeler E, Könsgen D, Hilpert F, von Kaisenberg CS, Pfisterer J, Bauknecht T, Jonat W, Arnold N, Hampton GM.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):458-66.

22.

A phosphoproteomic analysis of the ErbB2 receptor tyrosine kinase signaling pathways.

Mukherji M, Brill LM, Ficarro SB, Hampton GM, Schultz PG.

Biochemistry. 2006 Dec 26;45(51):15529-40. Epub 2006 Dec 19.

PMID:
17176074
23.

A novel method for gene expression mapping of metastatic competence in human bladder cancer.

Wu Z, Siadaty MS, Riddick G, Frierson HF Jr, Lee JK, Golden W, Knuutila S, Hampton GM, El-Rifai W, Theodorescu D.

Neoplasia. 2006 Mar;8(3):181-9.

24.

Comprehensive analysis of HE4 expression in normal and malignant human tissues.

Galgano MT, Hampton GM, Frierson HF Jr.

Mod Pathol. 2006 Jun;19(6):847-53.

25.

A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase.

Collins CS, Hong J, Sapinoso L, Zhou Y, Liu Z, Micklash K, Schultz PG, Hampton GM.

Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3775-80. Epub 2006 Feb 28.

26.

Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis.

Brown DA, Stephan C, Ward RL, Law M, Hunter M, Bauskin AR, Amin J, Jung K, Diamandis EP, Hampton GM, Russell PJ, Giles GG, Breit SN.

Clin Cancer Res. 2006 Jan 1;12(1):89-96.

27.

Overexpression of CEBPbeta correlates with decreased TFF1 in gastric cancer.

Sankpal NV, Moskaluk CA, Hampton GM, Powell SM.

Oncogene. 2006 Jan 26;25(4):643-9.

PMID:
16247479
28.

Mapping of candidate tumor suppressor genes on chromosome 12 in adenoid cystic carcinoma.

Rutherford S, Hampton GM, Frierson HF, Moskaluk CA.

Lab Invest. 2005 Sep;85(9):1076-85.

29.

Altered expression of TFF-1 and CES-2 in Barrett's Esophagus and associated adenocarcinomas.

Fox CA, Sapinoso LM, Zhang H, Zhang W, McLeod HL, Petroni GR, Mullick T, Moskaluk CA, Frierson HF, Hampton GM, Powell SM.

Neoplasia. 2005 Apr;7(4):407-16.

30.

Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.

Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M, Bauknecht T, Park TW, Jonat W, Jacobsen A, Sehouli J, Luttges J, Krajewski M, Krajewski S, Reed JC, Arnold N, Hampton GM.

Oncogene. 2005 Feb 3;24(6):1053-65.

PMID:
15558012
31.

Profiling the evolution of human metastatic bladder cancer.

Nicholson BE, Frierson HF, Conaway MR, Seraj JM, Harding MA, Hampton GM, Theodorescu D.

Cancer Res. 2004 Nov 1;64(21):7813-21.

32.

RNAi and HTS: exploring cancer by systematic loss-of-function.

Willingham AT, Deveraux QL, Hampton GM, Aza-Blanc P.

Oncogene. 2004 Nov 1;23(51):8392-400. Review.

PMID:
15517021
33.

Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin.

Wagner KW, Sapinoso LM, El-Rifai W, Frierson HF, Butz N, Mestan J, Hofmann F, Deveraux QL, Hampton GM.

Oncogene. 2004 Aug 26;23(39):6621-9.

PMID:
15208666
34.

Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer.

Theodorescu D, Sapinoso LM, Conaway MR, Oxford G, Hampton GM, Frierson HF Jr.

Clin Cancer Res. 2004 Jun 1;10(11):3800-6.

35.

Exposing oncogenic dependencies for cancer drug target discovery and validation using RNAi.

Deveraux QL, Aza-Blanc P, Wagner KW, Bauerschlag D, Cooke MP, Hampton GM.

Semin Cancer Biol. 2003 Aug;13(4):293-300. Review.

PMID:
14563124
36.

Overexpression of the 32-kilodalton dopamine and cyclic adenosine 3',5'-monophosphate-regulated phosphoprotein in common adenocarcinomas.

Beckler A, Moskaluk CA, Zaika A, Hampton GM, Powell SM, Frierson HF Jr, El-Rifai W.

Cancer. 2003 Oct 1;98(7):1547-51.

37.

Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays.

Moskaluk CA, Zhang H, Powell SM, Cerilli LA, Hampton GM, Frierson HF Jr.

Mod Pathol. 2003 Sep;16(9):913-9.

38.

Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas.

Frierson HF Jr, Moskaluk CA, Powell SM, Zhang H, Cerilli LA, Stoler MH, Cathro H, Hampton GM.

Hum Pathol. 2003 Jun;34(6):605-9.

PMID:
12827615
39.

An array of insights: application of DNA chip technology in the study of cell biology.

Panda S, Sato TK, Hampton GM, Hogenesch JB.

Trends Cell Biol. 2003 Mar;13(3):151-6. Review.

PMID:
12628348
40.

Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum.

Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, Ward RL, Hawkins NJ, Quinn DI, Russell PJ, Sutherland RL, Breit SN, Moskaluk CA, Frierson HF Jr, Hampton GM.

Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3410-5. Epub 2003 Mar 6.

41.

Classifying human cancer by analysis of gene expression.

Hampton GM, Frierson HF.

Trends Mol Med. 2003 Jan;9(1):5-10. Review.

PMID:
12524204
42.

RhoGDI2 is an invasion and metastasis suppressor gene in human cancer.

Gildea JJ, Seraj MJ, Oxford G, Harding MA, Hampton GM, Moskaluk CA, Frierson HF, Conaway MR, Theodorescu D.

Cancer Res. 2002 Nov 15;62(22):6418-23.

43.

Large scale molecular analysis identifies genes with altered expression in salivary adenoid cystic carcinoma.

Frierson HF Jr, El-Naggar AK, Welsh JB, Sapinoso LM, Su AI, Cheng J, Saku T, Moskaluk CA, Hampton GM.

Am J Pathol. 2002 Oct;161(4):1315-23.

44.

c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability.

Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM, Wahl GM.

Mol Cell. 2002 May;9(5):1031-44.

45.

Professionalism and the nurse-midwife practitioner: an exploratory study.

Hampton DL, Hampton GM.

J Am Acad Nurse Pract. 2000 Jun;12(6):218-25.

PMID:
11930444
46.

Large-scale analysis of the human and mouse transcriptomes.

Su AI, Cooke MP, Ching KA, Hakak Y, Walker JR, Wiltshire T, Orth AP, Vega RG, Sapinoso LM, Moqrich A, Patapoutian A, Hampton GM, Schultz PG, Hogenesch JB.

Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4465-70. Epub 2002 Mar 19.

47.

Molecular classification of human carcinomas by use of gene expression signatures.

Su AI, Welsh JB, Sapinoso LM, Kern SG, Dimitrov P, Lapp H, Schultz PG, Powell SM, Moskaluk CA, Frierson HF Jr, Hampton GM.

Cancer Res. 2001 Oct 15;61(20):7388-93.

48.

Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer.

Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF Jr, Hampton GM.

Cancer Res. 2001 Aug 15;61(16):5974-8.

49.

Arrays of arrays for high-throughput gene expression profiling.

Zarrinkar PP, Mainquist JK, Zamora M, Stern D, Welsh JB, Sapinoso LM, Hampton GM, Lockhart DJ.

Genome Res. 2001 Jul;11(7):1256-61.

50.

Clinical and pathologic significance of microsatellite instability in endometrial cancer.

Wong YF, Ip TY, Chung TK, Cheung TH, Hampton GM, Wang VW, Chang AM.

Int J Gynecol Cancer. 1999 Sep;9(5):406-410.

PMID:
11240802

Supplemental Content

Loading ...
Support Center